دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Community-based, cluster-randomized pilot trial of a cardiovascular mHealth intervention: Rationale, design, and baseline findings of the FAITH! Trial
LaPrincess C. Brewer, MD, MPH a,b , Sarah Jenkins, MS c , Sharonne N. Hayes, MD d , Ashok Kumbamu, PhD d , Clarence Jones, Med e , Lora E. Burke, PhD, MPH f , Lisa A. Cooper, MD, MPH g , and Christi A. Patten, PhD h Rochester, MN; Minneapolis, MN
doi : 10.1016/j.ahj.2022.01.009
Volume 247, May 2022, Pages 1-14
Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial
Roland Klingenberg, MD 1,2,# , Barbara E. Stähli, MD 1,# , Dik Heg, PhD 3 , Andrea Denegri, MD 1 , Robert Manka, MD 1 , Ioannis Kapos, MD 1 , Arnold von Eckardstein, MD 4 , David Carballo, MD 5 , Christian W. Hamm, MD 2 , Julia Vietheer, MD 2 , Andreas Rolf, MD 2 , Ulf Landmesser, MD 1,6 , François Mach, MD 5 , Tiziano Moccetti, MD 7 , Christian Jung, MD, PhD 8 , Malte Kelm, MD 8 , Thomas Münzel, MD 9 , Giovanni Pedrazzini, MD 7 , Lorenz Räber, MD, PhD 10 , Stephan Windecker, MD 10 , Christian M. Matter, MD 1,11 , Frank Ruschitzka, MD 1,§ , and Thomas F. Lüscher, MD 10,12,§ Switzerland; Bad Nauheim, Germany; Geneva, Switzerland; Berlin, Germany; Lugano, Switzerland; Duesseldorf, Germany; Mainz, Germany; Bern, Switzerland; Schlieren, Switzerland; London, U.K.
doi : 10.1016/j.ahj.2022.01.010
Volume 247, May 2022, Pages 33-41
Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation – Study protocol
Mark H. Eckman, MD, MS, Ruth Wise, MSN, MDes, Carol Knochelmann, RN, Rachael Mardis, BSN, RN, Sharon Wright, PharmD, Ashish Gummadi, MD, Estrelita Dixon, MD, Richard Becker, MD, Daniel P. Schauer, MD, MS, Matthew L. Flaherty, MD, Alexandru Costea, MD, Dawn Kleindorfer, MD, Rob Ireton, Pete Baker, BS, Brett M. Harnett, MS-IS, Adeboye Adejare, MS, Anthony C. Leonard, PhD, Heidi Sucharew, PhD, Amy Costanzo, RN, PhD, Lora Arduser, PhD, and John Kues, PhD Cincinnati, OH
doi : 10.1016/j.ahj.2022.01.012
Volume 247, May 2022, Pages 42-54
Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder and is a powerful common risk factor for stroke. Randomized trials have demonstrated that anticoagulation can reduce the risk of stroke in patients with AF.
The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study design
Tina Baykaner, MD, MPH a , Krishna Pundi, MD a , Bryant Lin, MD a , Ying Lu, PhD a , Katie DeSutter a , Karma Lhamo a , Gotzone Garay, PhD a , Julio C. Nunes, MD a , Daniel P. Morin, MD, MPH b , Samuel F. Sears, PhD c , Mina K. Chung, MD d , Michael K. Paasche-Orlow, MD, MA, MPH e , Lee M. Sanders, MD, MPH a , Thomas Jared Bunch, MD f , Mellanie True Hills g , Kenneth W. Mahaffey, MD a , Randall S. Stafford, MD, PhD a , and Paul J. Wang, MD a Palo Alto, CA
doi : 10.1016/j.ahj.2022.01.013
Volume 247, May 2022, Pages 68-75
Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial
Min Soo Cho, MD a,1 , Do-Yoon Kang, MD a,1 , Yong-Seog Oh, MD b , Chang Hoon Lee, MD c , Eue-Keun Choi, MD d , Ji Hyun Lee, MD e , Chang Hee Kwon, MD f , Gyung-Min Park, MD g , Hyun Woo Park, MD h , Kyoung-Ha Park, MD i , Kyoung-Min Park, MD j , Jongmin Hwang, MD k , Ki-Dong Yoo, MD l , Young-Rak Cho, MD m , Yoo Ri Kim, MD n , Ki Won Hwang, MD o , Eun Sun Jin, MD p , Pum-Joon Kim, MD q , Ki Hun Kim, MD r , Duk-Woo Park, MD a , and Gi-Byoung Nam, MD a Seoul, South Korea
doi : 10.1016/j.ahj.2022.01.014
Volume 247, May 2022, Pages 123-131
Anticoagulants are the standard therapy for patients with atrial fibrillation (AF) and antiplatelet therapy for those with coronary artery disease (CAD). However, compelling clinical evidence is still lacking regarding the long-term maintenance strategy with the combination of anticoagulant and antiplatelet drugs in patients with AF and stable CAD.
Clinical decision support for familial hypercholesterolemia (CDS-FH): Rationale and design of a cluster randomized trial in primary care
Olof Persson Lindell, MD a,b,†, Lars O Karlsson, MD PhD a,b,†, Staffan Nilsson, MD PhD b,c , Emmanouil Charitakis, MD PhD a,b , Emil Hagström, MD PhD d,e , Thomas Muhr, MD a , Lennart Nilsson, MD PhD b,f , Martin Henriksson, PhD g , and Magnus Janzon, MD PhD a,b Linkoping, Sweden; Uppsala, Sweden; Jonkoping, Sweden
doi : 10.1016/j.ahj.2022.02.005
Volume 247, May 2022, Pages 132-148
Trends of blood pressure control in the U.S. during the COVID-19 pandemic
Nishant P. Shah, MD a,b , Robert M. Clare a , Karen Chiswell, PhD a , Ann Marie Navar, MD, PhD d , Bimal R. Shah, MD b,c , and Eric D. Peterson, MD, MPH d Durham, NC; Purchase, NY
doi : 10.1016/j.ahj.2021.11.017
Volume 247, May 2022, Pages 15-23
COVID-19 altered lifestyles and disrupted routine health care. Whether blood pressure (BP) control worsened during COVID-19 is unknown.
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups
Baris Gencer, MD, MPH a,b,c , Alon Eisen, MD d , David Berger, MD d , Francesco Nordio, PhD a , Sabina A. Murphy, MPH a , Laura T. Grip, MSc a , Cathy Chen, MD e , Hans Lanz, MD f , Christian T. Ruff, MD, MPH a , Elliott M Antman, MD a , Eugene Braunwald, MD a , and Robert P Giugliano, MD, SM a Boston, MA; Geneva, Switzerland
doi : 10.1016/j.ahj.2021.12.017
Volume 247, May 2022, Pages 24-32
Atrial fibrillation detection using ambulatory smartwatch photoplethysmography and validation with simultaneous holter recording
Po-Cheng Chang, MD, Ming-Shien Wen, MD, Chung-Chuan Chou, MD, Chun-Chieh Wang, MD, and Kuo-Chun Hung, MD Taoyuan, Taiwan
doi : 10.1016/j.ahj.2022.02.002
Volume 247, May 2022, Pages 55-62
Atrial fibrillation (AF)-associated embolic stroke is preventable, and AF detection may help to prevent stroke in subjects with paroxysmal AF. We aimed to evaluate the AF detection performance of smartwatch photoplethysmography (PPG) and the feasibility of ambulatory monitoring for AF detection in the daily life.
A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
Abhinav Sharma, MD, PhD a,b , Malik Elharram, MD, MSc a,b , Jonathan Afilalo, MD, MSc c , Alexandria Flannery, RN b , Marc Afilalo, MD d , Chris Tselios, MD d , Jiayi Ni, MSc a,b , Justin A. Ezekowitz, MBBCh, MSc e , Matthew P. Cheng, MDCM f , Andrew P. Ambrosy, MD g,h , Faiez Zannad, MD, PhD i , James M. Brophy, MD, PhD a , Nadia Giannetti, MD a , Amal Bessissow, MD, MSc j , Nadine Kronfli, MD, MPH f , Ariane Marelli, MD, MPH a , Haya Aziz, MDCM a , Mohammad Alqahtani, MD j , Mona Aflaki, MD, PhD j , Morgan Craig, PhD k , Renato D. Lopes, MD, PhD l , and João Pedro Ferreira, MD, PhD i,m Quebec, Canada; Alberta, Canada; San Francisco, CA; Oakland, CA; Nancy, France; Durham, NC
doi : 10.1016/j.ahj.2022.01.015
Volume 247, May 2022, Pages 76-89
Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart – portable extracorporeal heart perfusion and monitoring system
Mohit Pahuja, MD a , Brian C. Case, MD a , Ezequiel J. Molina, MD b , and Ron Waksman, MD a Washington, DC
doi : 10.1016/j.ahj.2022.02.003
Volume 247, May 2022, Pages 90-99
There are a limited number of donor hearts available for transplantation every year, and an even lower number of these hearts actually undergo transplantation. One of the barriers to utilizing donor hearts is the inferior outcomes associated with prolonged ischemic times.
Associations of maternal angiogenic factors during pregnancy with alterations in cardiac development in childhood at 10 years of age
Meddy N. Bongers-Karmaoui, MD a,b , Vincent W.V. Jaddoe, MDPhD a,b , Arno A.W. Roest, MDPhD c , Willem A. Helbing, MDPhD b , Eric A.P. Steegers, MDPhD d , and Romy Gaillard, MDPhD a,b Rotterdam, The Netherlands; Leiden, The Netherlands
doi : 10.1016/j.ahj.2022.01.016
Volume 247, May 2022, Pages 100-111
Stroke events after transcatheter aortic valve implantation: Temporal relationships and affected brain regions
Matthias Linder, MD a , Focko Lorenz Higgen, MD b , Lisa Voigtländer, MD a,d , Jessica Weimann, MSc a , Sebastian Ludwig, MD a , Lara Waldschmidt, MD a , Charlotte Focke, BSc a , Oliver Daniel Bhadra, MD c , David Grundmann, MD a , Till Joscha Demal, MD c , Andreas von Zastrow, BSc a , Andreas Schäfer, MD c , Johannes Schirmer, MD c , Hermann Reichenspurner, MDPhD c , Stefan Blankenberg, MD a,d , Dirk Westermann, MD a,d , Niklas Schofer, MD a , Lenard Conradi, MD c , Götz Thomalla, MD b , and Moritz Seiffert, MD a,d Hamburg, Germany
doi : 10.1016/j.ahj.2022.02.004
Volume 247, May 2022, Pages 112-122
Despite continuous improvements in transcatheter aortic valve implantation (TAVI), periprocedural strokes remain a devastating complication. Randomized controlled trials failed to demonstrate a reduction in clinically apparent strokes or mortality after TAVI due to cerebral embolic protection (CEP).
Female sex-specific and -predominant cardiovascular risk factors and heart failure practice guidelines
Rana Hassan, MD a,b , Victoria J Riehl-Tonn, BN a,b , Sandra M Dumanski, MD MSc a,b,c , Kristin J Lyons, MD a,b , and Sofia B Ahmed, MD MMSc a,b,c Alberta, Canada
doi : 10.1016/j.ahj.2022.01.007
Volume 247, May 2022, Pages 63-67
